| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Pathology and Microbiology, University of Nebraska Medical Center, 987660 Nebraska Medical Center, Omaha, NE 68198
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Angiogenesis is a multistep process including endothelial cell proliferation and migration by degradation of the extracellular matrix by matrix metalloproteinases (MMPs)3 (17) and capillary tube formation which is mediated by various angiogenic factors such as vascular endothelial growth factor, basic fibroblast growth factor, and IL-8 (18). Recent reports suggest that in addition to cell proliferation and migration, endothelial cell survival and death are also important components for tumor angiogenesis (19). Recent studies have shown that a cell cycle-regulated apoptosis inhibitor, survivin (20, 21), and the cell death-related gene family, Bcl-2 (22), are associated with vascular endothelial growth factor-induced angiogenesis (23, 24, 25). IL-8 and its receptors, CXCR1 and CXCR2, have been observed on endothelial cells (7, 8) and have been shown to play a role in endothelial cell proliferation (5). However, these findings remain controversial and a direct role of IL-8 in angiogenesis is not well established. In the present study, we provide evidences to support the direct role of IL-8 in angiogenesis by enhancing proliferation and survival and inhibiting apoptosis of CXCR1- and CXCR2-expressing endothelial cells. Furthermore, treatment of endothelial cells with IL-8 significantly enhanced production of MMPs and capillary tube organization.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
HUVEC and dermal microvascular endothelial cells (HMEC) were obtained from American Type Culture Collection (ATCC, Manassas, VA) and (Cambrex Biosciences, Walkersville, MD). These cell lines were maintained in culture as an adherent monolayer in endothelial cell medium supplemented with 10% FBS and endothelial cell growth supplement (EGM-2 MV; Cambrex Biosciences). Recombinant human IL-8, growth-regulated oncogene 
(gro-, also known as CXCL-1) and anti-IL-8 Abs were purchased from R&D Systems (Minneapolis, MN).
In vitro proliferation and apoptosis assay
Endothelial cells were seeded into 6-well (cell counting) and 96-well ([3H]thymidine incorporation) flat-bottom plates in duplicate or triplicate and allowed to adhere overnight. The cultures were then washed and refed with medium alone (control) or medium containing different concentrations of recombinant human IL-8. Following 96 h of incubation, cell proliferation was determined by cell counting and [3H]thymidine incorporation. For [3H]thymidine incorporation, cultures were pulse labeled with [3H]thymidine (1 µCi/well) and washed, and radioactivity was measured using a beta counter. For cell counting, cells were trypsinized and viable cells were counted using a hemocytometer. Percent growth stimulation was calculated as growth stimulation = (A/B) -1 x 100, where A is the number of viable cells in treated cultures and B is the number of viable cells in untreated control cultures.
To determine whether IL-8 treatment inhibited apoptosis and enhanced survival, endothelial cells (1 x 105 cells/well) in four-well chambered slides were incubated with medium alone or medium containing 1 or 10 ng/ml IL-8. Following 72 h in culture, cells were stained with a CaspACE FITC-valylalanylaspartyl [O-methyl]fluoromethoxyketoneVAD-fmk in situ marker kit (Promega, Madison, WI) according to the manufacturer’s protocol. The number of apoptotic cells was determined by counting the average numbers of immunostained cells in five independent high-power fields (x200), each containing 50–100 cells using a Nikon fluorescence microscope (Nikon, Melville, NY).
In vitro capillary tube formation assay
An in vitro capillary tube formation assay was performed as described earlier (26). Briefly, 5 x 104 HUVEC were plated on a Matrigel (BD Biosciences, Mountain View, CA)-coated 24-well plate with medium alone or medium containing IL-8, fibroblast growth factor 2 (FGF-2), or neutralizing Ab to IL-8. Following 6 h of incubation, the plate was examined for capillary tube formation under an inverted microscope and photographed. Each assay was done in duplicate and each experiment was repeated three times. The qualitative difference in tube formation was examined in treated or untreated cultures.
Zymogram for MMP activity
Culture supernatants from 5 x 105 endothelial cells were used for gelatin zymography as described previously (27). Briefly, the gelatin-degrading activity in the culture supernatants was analyzed by electrophoresis on an 8% SDS-PAGE-containing gelatin (1.5 mg/ml) without prior heating or reduction. Following electrophoresis, the gel was washed in 2.5% Triton X-100 to remove SDS, incubated in 50 mM Tris-HCl buffer (pH 7.5), containing 0.15 M NaCl, 10 mM CaCl2, and 0.02% (w/v) NaN3 with or without EDTA for 16 h at 37°C and stained with 0.1% Coomassie brilliant blue R250 (Sigma-Aldrich, St. Louis, MO). Gelatinolytic activity was visualized by negative staining. Prestained SDS-PAGE protein standards (Bio-Rad, Richmond, VA) were used for estimating molecular mass.
Endothelial cell migration assay
Endothelial cell migration in response to IL-8 was determined as described earlier (28, 29). Transwell chambers (6.5 mm) (Corning Costar, Cambridge, MA) with polycarbonate membrane containing 8.0-µm pores were coated with matrigel. Endothelial cells (5 x 104) were plated onto transwell chambers with medium (serum free) alone or medium containing different concentrations of IL-8 in duplicate and incubated at 37°C in CO2 for 4 h. MTT was added and cells were incubated for an additional 2 h. Cells from the top of the Transwell chambers were removed using a cotton swab (residual cells). Cotton swabs containing residual cells and transwell chamber (migrated) cells were placed in 24-well plates containing 400 µl of DMSO. Following 1 h of gentle shaking, 100-µl samples were removed and absorbency was determined at 570 nm using an ELISA plate reader. The percent migratory activity was calculated as: percent migration = A/[(A + B] x 100, where A is the absorbance of migrated cells and B is the absorbance of residual cells.
Immunocytochemical (ICC) analysis
CXCR1 and CXCR2 protein expression in HUVEC and HMEC was analyzed by ICC. Briefly, cells (1 x 105) were plated in four-well chambered slides. The cells were cultured for 72 h and used for immunostaining. Samples were washed twice with PBS and fixed with 4% glutaraldehyde (Sigma-Aldrich) in PBS for 10 min. After washing twice with PBS, cells were incubated with a blocking solution containing 5% normal horse serum in PBS for 20 min at room temperature. Excess blocking solution was drained and samples were incubated with a 1/200 dilution of anti-CXCR1 or anti-CXCR2 Ab or isotype control Ab (BD PharMingen, San Diego, CA) overnight at 4°C in a humidified chamber. The samples were then rinsed four times with PBS and incubated with a 1/500 dilution of biotinylated horse anti-mouse/rabbit IgG (Vector Laboratories, Burlingame, CA). The ICC reaction was detected using the avidin-biotin complex Elite and diaminobenzidine substrate kits (Vector Laboratories) according to the manufacturer’s instructions. A reddish brown precipitate in the cytoplasm indicated a positive reaction. Negative controls used all reagents except the primary Ab.
Receptor-ligand binding assay
Endothelial cells were allowed to adhere overnight, washed, and refed with HBSS containing 125I-IL-8 at different concentrations alone or in combination with 100-fold molar excess IL-8 or gro- in the binding buffer (HEPES buffer containing 0.1% BSA). The reactions were carried out at room temperature for 1 h, the cells were washed extensively with binding buffer and lysed in 0.1 N NaOH, and cell-associated radioactivity was measured in a gamma counter. Nonspecific binding was determined using a 100-fold excess of unlabeled ligand. Data were analyzed by the Scatchard method using Graph Prism software (GrapPad, San Diego, CA) and presented as specific binding.
Flow cytometry analysis
Cell surface expression of CXCR1 and CXCR2 on HUVEC was analyzed by flow cytometry using PE- and FITC-labeled anti-CXCR1 and CXCR2 Ab (BD PharMingen). We performed dual staining to obtain the information regarding the expression of both receptors on the specific cell population. Data were acquired on a BD Biosciences (San Jose, CA) FACStarPlus and analyzed by using the Attractors and CellQuest software.
mRNA analysis
Total cellular RNA was isolated from endothelial cells (1 x 106 cells) using TRIZOL reagent (Life Technologies, Gaithersburg, MD). RT-PCR was performed as described earlier (30). Briefly, cDNA was synthesized using total RNA (2 µg), oligo(dT)12–18 primer, and superscript RT (Life Technologies). Two microtiters of first-strand cDNA (1/10 dilutions) was amplified using PCR primer sets (Table I). The primers were synthesized by Sigma-Genosys (Woodlands, TX). Each cycle set used a denaturing temperature (94°C) for 60 s, annealing temperature (55°C) for 90 s, and extension temperature (72°C) for 90 s for a total of 30 cycles for each primer, except GAPDH where it was 20 cycles. PCR fragments were separated on a 2% agarose gel containing ethidium bromide (0.5 µg/ml), visualized, and photographed using an Alpha Imager Gel Documentation System (Alpha Innotech, San Leanardo, CA). Semiquantitative mRNA analysis was performed using an equal number of cells with simultaneous amplification in the linear range. Relative intensity of the specific gene expression was determined with Alpha Ease (Alpha Innotech). mRNA expression was presented as expression index, the ratio of each signal to the signal from the housekeeping gene GAPDH. The expression index for cells cultured with medium alone was arbitrarily set to 1 to represent the difference in the expression level among HUVEC treated with different concentrations of IL-8.
|
Cell extracts from treated and untreated HUVEC were quantitated by a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Equal amounts of proteins (20 µg/lane) were separated on SDS-PAGE and electrotransferred to 0.45-µm nitrocellulose membranes. The membranes were blocked with 3% BSA and probed with anti-bcl-2 (1:100) and bax (1:200), followed by biotinylated anti-IgG and alkaline phosphatase-streptavidin (Vector Laboratories). Protein bands were visualized by an enhanced chemifluorescence detection system according to the manufacturer’s protocol and analyzed using a PhosphorImager and ImageQuant software (Molecular Dynamics, Sunnyvale, CA). Relative intensity of the specific protein expression was determined using ImageQuant 5.1 (Molecular Dynamics).
Statistical analysis
The significance of the data was determined by Student’s t test (two-tailed) using SPSS software (SPSS, Chicago, IL). A value of p < 0.05 was deemed significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Expression of CXCR1 and CXCR2 on endothelial cells and their role in angiogenesis remains controversial. Therefore, in the first experiment, we determined whether HUVEC and HMEC express CXCR1 and CXCR2 by ICC, flow cytometry, and RT-PCR analysis. HUVEC and HMEC were fixed and immunostained with anti-CXCR1 or anti-CXCR2 Ab. Strong positive immunostaining was observed with CXCR1 and CXCR2 Abs in HUVEC and HMEC (Fig. 1A, a–d). We did not observe immunostaining in cells incubated with control isotype Ab (Fig. 1A, e and f). CXCR1 and CXCR2 mRNA expression was analyzed by semiquantitative RT-PCR mRNA analysis. We observed constitutive expression of CXCR1- and CXCR2-specific mRNA expression in HUVEC and HMEC (Fig. 1B). We confirmed these observation by flow cytometry. We observed cell surface expression of both CXCR1 and CXCR2 expression in HMEC (Fig. 1C).
|
was examined. Results shown in Fig. 1D demonstrate that IL-8 binds to its receptor on endothelial cells, which can be blocked with IL-8 and gro- (Fig. 1D). Interestingly, we observed that blocking of 125I-IL-8 binding to HUVEC was lower with gro- (which binds to CXCR2) as compared to IL-8 (which binds to CXCR1 and CXCR2), suggesting that both receptors are expressed on HUVEC. These data demonstrate that CXCR1 and CXCR2 mRNA and proteins are constitutively expressed in endothelial cells. Induction of endothelial cell proliferation by IL-8
We examined the effect of IL-8 on HUVEC and HMEC proliferation. HUVEC or HMEC were treated for 96 h with medium alone or medium containing recombinant human IL-8 at different concentrations. Endothelial cell proliferation was determined by analyzing the number of viable cells and [3H]thymidine incorporation in treated and untreated cultures. Treatment of HUVEC with IL-8 significantly enhanced endothelial cell proliferation as compared with untreated cells (Fig. 2A). Treatment of HMEC with IL-8 also enhanced endothelial cell proliferation (not significantly) as compared with untreated cells (Fig. 2B). We did not observe significant differences in HUVEC and HMEC number in cultures treated with 10 and 100 ng/ml IL-8 (Fig. 2, A and B).
|
IL-8 inhibits spontaneous apoptosis of endothelial cells
We determined whether IL-8 treatment of HUVEC and HMEC inhibited apoptosis and enhanced their survival. Endothelial cells cultured in four-well chambered slides were treated with medium alone or medium containing 1 or 10 ng/ml IL-8 for 72 h. Cells were immunostained for apoptosis using the CaspACE-FITC kit. Apoptotic cells were stained positive and were counted using fluorescence microscopy. Our data demonstrate a significantly higher frequency of apoptotic cells in untreated HUVEC (Fig. 3) and HMEC (data not shown). In contrast, the addition of IL-8 significantly inhibited the apoptosis of endothelial cells (Fig. 3), suggesting that IL-8 inhibits apoptosis and functions as a survival factor for endothelial cells.
|
Total RNA was isolated from endothelial cells treated with medium alone or medium containing IL-8 and mRNA expression of pro- and antiapoptotic genes was detected by RT-PCR (Fig. 4). We observed no increase in survinin mRNA expression between untreated and IL-8-treated HUVEC (Fig. 4). IL-8-treatment enhanced mRNA for antiapoptotic Bcl-xL (378 bp) and proapoptotic Bcl-xS (190 bp) genes (Fig. 4A). Similarly, treatment of endothelial cells with IL-8 also enhanced Bcl-2 mRNA expression and down-regulated Bax mRNA expression (Fig. 4B). However, the increase in Bcl-xL expression was much higher than in Bcl-xS, leading to an elevated ratio of Bcl-xL: to Bcl-xS (Fig. 4). Similar to mRNA data, our Western blot analysis demonstrates that IL-8 treatment up-regulated Bcl-2 (antiapoptotic) protein and decreased Bax (proapoptotic) protein productions in a concentration-dependent manner (Fig. 4C). These results suggest that IL-8 promoted endothelial cell survival by enhancing expression of antiapoptotic survival-associated genes in endothelial cells.
|
We examined MMP-2 and MMP-9 mRNA and activity in endothelial cells cultured in medium (phenol free, serum-free RPMI 1640) alone or medium containing different concentrations of IL-8. MMP-2 and MMP-9 mRNA expression was increased in cells treated with 10 and 100 ng/ml IL-8 (Fig. 5A). Culture supernatant collected from endothelial cells treated with medium containing IL-8 showed higher levels of active MMP-2 and MMP-9 production (Fig. 5B).
|
Earlier studies have demonstrated that IL-8 is a chemotactic factor for endothelial cells (5). We examined the effect of IL-8 on CXCR1- and CXCR2-expressing endothelial cell migration. We observed a concentration-dependent, significantly enhanced migration of endothelial cells incubated with IL-8 as compared to cells incubated with medium alone (Fig. 6).
|
Next, we examined the effect of IL-8 on endothelial cell organization into capillary tube structures. Endothelial cells were plated on a Matrigel-coated 24-well plate with medium alone or medium containing IL-8 (10 ng/ml), FGF-2 (10 ng/ml), or IL-8 (10 ng/ml) with neutralizing Ab to IL-8 (10 µg/ml). After 6 h of incubation, plates were examined for capillary tube formation under an inverted microscope. We observed increased capillary tube formation in endothelial cells incubated with medium containing IL-8 and FGF-2 (Fig. 7). In addition, cultures treated with both IL-8 and neutralizing Ab to IL-8 demonstrated reduced capillary tube formation compared with cells incubated with medium alone or with IL-8 alone (Fig. 7), suggesting the specificity and direct effect of IL-8 in mediating endothelial cell capillary tube formation.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
IL-8 is widely expressed in tumor, stroma, and endothelial cells (9, 10, 11, 12, 13). Its autocrine and paracrine function has been shown to play an important role in angiogenesis (5, 6, 7, 8, 11), tumor growth, and metastasis (12, 35, 36). However, the direct role of IL-8 in angiogenesis remains unclear. We observed that IL-8 stimulates endothelial cell proliferation and capillary tube organization in a concentration-dependent manner, which can be blocked by neutralizing anti-IL-8 Abs, suggesting that IL-8 promotes angiogenesis by directly interacting with endothelial cells. Furthermore, our data suggest that endothelial cell proliferation, survival, expression of survival-associated genes and MMPs depend on the concentration of IL-8 used. Since angiogenesis is essential for tumor progression and metastasis (3, 4, 37), these data suggest that IL-8 plays an autocrine/paracrine role in tumor growth and metastasis (11).
Endothelial cell survival and programmed cell death are critical for maintenance of vascular structure in angiogenesis (19). When HUVEC were cultured in medium devoid of growth factors, large numbers of endothelial cells were dead after 72 h in culture. However, adding IL-8 to these cultures significantly enhanced the survival of cultured HUVEC. In one of the earlier studies, Nor et al. (38) demonstrated that IL-8 did not inhibit the apoptosis of human dermal microvascular endothelial cells. The observed differences could be due to differences in the cell lines used in these studies. IL-8 has been implicated as a survival factor for endothelial cells and a key mediator of angiogenesis for several tumors, including carcinoma of lung, colon, oral cavity, Kaposi’s sarcoma, and melanoma (5, 10, 38, 39, 40, 41, 42, 43, 44). The mechanism by which IL-8 exerts its antiapoptotic effect is not clear. Earlier studies suggest that IL-8-mediated inhibition of apoptosis could be dependent or independent of Bcl-2 expression (38, 45, 46).
Differential expression of Bcl-2 family members, which includes antiapoptotic (Bcl-2 and Bcl-xL) and proapoptotic (Bax and Bcl-xS) genes, regulates apoptosis (22). Bcl-xL and Bcl-xS are splice variants of the Bcl-x gene (47). The Bcl-2 and Bcl-xL genes interact with Bax to suppress apoptosis, while Bcl-xS promotes cell death by inhibiting Bcl-2 and Bcl-xL (22). Constitutive expression of Bcl-x has been shown in HUVEC as reported by Ackermann et al. (48). The enhanced Bcl-xL expression levels coupled with increased Bcl-xS expression levels were observed in IL-8-treated HUVEC. IL-8 also induced increased Bcl-2 and decreased Bax expression in endothelial cells, tilting the balance in favor of an antiapoptotic effect of IL-8. Although there was increased Bcl-xS gene expression in IL-8-treated HUVEC, we observed an increased ratio of Bcl-xL:Bcl-xS following treatment with recombinant human IL-8. The ratio of Bcl-2:Bax and Bcl-xL:Bcl-xS can reflect enhanced endothelial cell survival (49). A recent report demonstrates the association between Bcl-2 expression and IL-8 production and their interdependence in angiogenesis in vivo (38). These data suggest that IL-8 might regulate angiogenesis by modulating the endothelial cell antiapoptosis pathway.
Tumor angiogenesis is a complex process that is regulated by a balance between angiogenic and antiangiogenic factors (18, 50), which are influenced by the tumor cell itself and/or the tumor microenvironment (18). Degradation of the extracellular matrix by MMPs is required in endothelial cell migration, organization, and, hence, angiogenesis (17, 18). Recent reports suggest that IL-8 up-regulates MMP-2 expression in human melanoma cells (51). In the present study, the mRNA levels, as well as active MMP-2 and MMP-9 expression in endothelial cells, were enhanced by recombinant human IL-8, suggesting that IL-8 is involved in the degradation of extracellular matrix, leading to endothelial cell migration, invasion, and capillary tube organization.
In conclusion, IL-8 may be a potential endothelial cell growth and survival factor, interacting through its receptors expressed by endothelial cells. The mechanism of IL-8 regulation of angiogenesis may be in part due to enhanced proliferation and survival of endothelial cells by differential expression of antiapoptosis genes and in part by activation of MMP-2 and MMP-9. The development of strategies to block IL-8 production and/or activity may hold promise in limiting the deleterious effects of IL-8-mediated angiogenesis in various disease states, including malignant tumors.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Rakesh K. Singh, Department of Pathology and Microbiology, University of Nebraska Medical Center, 987660 Nebraska Medical Center, Omaha, NE 68198-7660. E-mail address: rsingh{at}unmc.edu
3 Abbreviations used in this paper: MMP, matrix metalloproteinase; HMEC, human dermal microvascular endothelial cell; ICC, immunocytochemistry; FGF-2, fibroblast growth factor 2; gro-, growth-regulated oncogene.
Received for publication January 15, 2002. Accepted for publication January 14, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
upregulates MMP-9 expression in stromal cells of human giant cell tumor of bone. J. Interferon Cytokine Res. 19:1207.[Medline]
This article has been cited by other articles:
|
|
 |
|
  E. B. Breitschwerdt, R. G. Maggi, M. Varanat, K. E. Linder, and G. Weinberg Isolation of Bartonella vinsonii subsp. berkhoffii Genotype II from a Boy with Epithelioid Hemangioendothelioma and a Dog with Hemangiopericytoma J. Clin. Microbiol., June 1, 2009; 47(6): 1957 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gavard, X. Hou, Y. Qu, A. Masedunskas, D. Martin, R. Weigert, X. Li, and J. S. Gutkind A Role for a CXCR2/Phosphatidylinositol 3-Kinase {gamma} Signaling Axis in Acute and Chronic Vascular Permeability Mol. Cell. Biol., May 1, 2009; 29(9): 2469 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Russo, R. Guabiraba, C. C. Garcia, L. S. Barcelos, E. Roffe, A. L. S. Souza, F. A. Amaral, D. Cisalpino, G. D. Cassali, A. Doni, et al. Role of the Chemokine Receptor CXCR2 in Bleomycin-Induced Pulmonary Inflammation and Fibrosis Am. J. Respir. Cell Mol. Biol., April 1, 2009; 40(4): 410 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Singh, A. Sadanandam, K. C. Nannuru, M. L. Varney, R. Mayer-Ezell, R. Bond, and R. K. Singh Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis Clin. Cancer Res., April 1, 2009; 15(7): 2380 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Shaik, T. D. Soltau, G. Chaturvedi, B. Totapally, J. S. Hagood, W. W. Andrews, M. Athar, N. N. Voitenok, C. R. Killingsworth, R. P. Patel, et al. Low Intensity Shear Stress Increases Endothelial ELR+ CXC Chemokine Production via a Focal Adhesion Kinase-p38{beta} MAPK-NF-{kappa}B Pathway J. Biol. Chem., February 27, 2009; 284(9): 5945 - 5955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Abdel-Malak, M. Mofarrahi, D. Mayaki, L. M. Khachigian, and S. N.A. Hussain Early Growth Response-1 Regulates Angiopoietin-1-Induced Endothelial Cell Proliferation, Migration, and Differentiation Arterioscler. Thromb. Vasc. Biol., February 1, 2009; 29(2): 209 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Singh, M. Varney, and R. K. Singh Host CXCR2-Dependent Regulation of Melanoma Growth, Angiogenesis, and Experimental Lung Metastasis Cancer Res., January 15, 2009; 69(2): 411 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bendrik and C. Dabrosin Estradiol Increases IL-8 Secretion of Normal Human Breast Tissue and Breast Cancer In Vivo J. Immunol., January 1, 2009; 182(1): 371 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Brant and J. P. Fabisiak Nickel and the Microbial Toxin, MALP-2, Stimulate Proangiogenic Mediators from Human Lung Fibroblasts via a HIF-1{alpha} and COX-2-Mediated Pathway Toxicol. Sci., January 1, 2009; 107(1): 227 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Schultheis, G. Lurje, K. E. Rhodes, W. Zhang, D. Yang, A. A. Garcia, R. Morgan, D. Gandara, S. Scudder, A. Oza, et al. Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab Clin. Cancer Res., November 15, 2008; 14(22): 7554 - 7563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Thapa, J. S. Lee, S.-Y. Park, Y.-H. Bae, S.-K. Bae, J. B. Kwon, K.-J. Kim, M.-K. Kwak, Y.-J. Park, H. G. Choi, et al. Clotrimazole Ameliorates Intestinal Inflammation and Abnormal Angiogenesis by Inhibiting Interleukin-8 Expression through a Nuclear Factor-{kappa}B-Dependent Manner J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 353 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J.J. Waugh and C. Wilson The Interleukin-8 Pathway in Cancer Clin. Cancer Res., November 1, 2008; 14(21): 6735 - 6741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shibata, K. Nakagawa, P. Sookwong, T. Tsuduki, S. Tomita, H. Shirakawa, M. Komai, and T. Miyazawa Tocotrienol Inhibits Secretion of Angiogenic Factors from Human Colorectal Adenocarcinoma Cells by Suppressing Hypoxia-Inducible Factor-1{alpha} J. Nutr., November 1, 2008; 138(11): 2136 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lurje, W. Zhang, A. M. Schultheis, D. Yang, S. Groshen, A. E. Hendifar, H. Husain, M. A. Gordon, F. Nagashima, H. M. Chang, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer Ann. Onc., October 1, 2008; 19(10): 1734 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Madonna, C. Scarponi, O. De Pita, and C. Albanesi Suppressor of cytokine signaling 1 inhibits IFN-{gamma} inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation FASEB J, September 1, 2008; 22(9): 3287 - 3297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Movahedi, C. Gysemans, D. Jacobs-Tulleneers-Thevissen, C. Mathieu, and D. Pipeleers Pancreatic Duct Cells in Human Islet Cell Preparations Are a Source of Angiogenic Cytokines Interleukin-8 and Vascular Endothelial Growth Factor Diabetes, August 1, 2008; 57(8): 2128 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Beswick and V. E. Reyes Macrophage Migration Inhibitory Factor and Interleukin-8 Produced by Gastric Epithelial Cells during Helicobacter pylori Exposure Induce Expression and Activation of the Epidermal Growth Factor Receptor Infect. Immun., July 1, 2008; 76(7): 3233 - 3240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.H. Nissim Ben Efraim and F. Levi-Schaffer Review: Tissue remodeling and angiogenesis in asthma: the role of the eosinophil Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 163 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 N. A. Abdel-Malak, C. B. Srikant, A. S. Kristof, S. A. Magder, J. A. Di Battista, and S. N. A. Hussain Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8 Blood, April 15, 2008; 111(8): 4145 - 4154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Scupoli, M. Donadelli, F. Cioffi, M. Rossi, O. Perbellini, G. Malpeli, S. Corbioli, F. Vinante, M. Krampera, M. Palmieri, et al. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-{kappa}B and JNK/AP-1 pathways Haematologica, April 1, 2008; 93(4): 524 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Merritt, Y. G. Lin, W. A. Spannuth, M. S. Fletcher, A. A. Kamat, L. Y. Han, C. N. Landen, N. Jennings, K. De Geest, R. R. Langley, et al. Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell Growth J Natl Cancer Inst, March 5, 2008; 100(5): 359 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Petreaca, M. Yao, Y. Liu, K. DeFea, and M. Martins-Green Transactivation of Vascular Endothelial Growth Factor Receptor-2 by Interleukin-8 (IL-8/CXCL8) Is Required for IL-8/CXCL8-induced Endothelial Permeability Mol. Biol. Cell, December 1, 2007; 18(12): 5014 - 5023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-Y. Oh, C.-H. Yoon, J. Hur, J.-H. Kim, T.-Y. Kim, C.-S. Lee, K.-W. Park, I.-H. Chae, B.-H. Oh, Y.-B. Park, et al. Involvement of E-selectin in recruitment of endothelial progenitor cells and angiogenesis in ischemic muscle Blood, December 1, 2007; 110(12): 3891 - 3899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kanayasu-Toyoda, A. Ishii-Watabe, T. Suzuki, T. Oshizawa, and T. Yamaguchi A New Role of Thrombopoietin Enhancing ex Vivo Expansion of Endothelial Precursor Cells Derived from AC133-positive Cells J. Biol. Chem., November 16, 2007; 282(46): 33507 - 33514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Park, H.-J. Kwak, H.-C. Lee, D.-H. Yoo, I.-C. Park, M.-S. Kim, S.-H. Lee, C. H. Rhee, and S.-I. Hong Nerve Growth Factor Induces Endothelial Cell Invasion and Cord Formation by Promoting Matrix Metalloproteinase-2 Expression through the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway and AP-2 Transcription Factor J. Biol. Chem., October 19, 2007; 282(42): 30485 - 30496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Gross, J. O. Boyle, B. Du, V. D. Kekatpure, A. Lantowski, H. T. Thaler, B. B. Weksler, K. Subbaramaiah, and A. J. Dannenberg Inhibition of Jun NH2-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., October 1, 2007; 13(19): 5910 - 5917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Affara, B. Dunmore, C. Savoie, S. Imoto, Y. Tamada, H. Araki, D. S. Charnock-Jones, S. Miyano, and C. Print Understanding endothelial cell apoptosis: what can the transcriptome, glycome and proteome reveal? Phil Trans R Soc B, August 29, 2007; 362(1484): 1469 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sanchez, A. Moldobaeva, J. McClintock, J. Jenkins, and E. Wagner The role of CXCR2 in systemic neovascularization of the mouse lung J Appl Physiol, August 1, 2007; 103(2): 594 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Giorgini, D. Trisciuoglio, C. Gabellini, M. Desideri, L. Castellini, C. Colarossi, U. Zangemeister-Wittke, G. Zupi, and D. Del Bufalo Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression Mol. Cancer Res., August 1, 2007; 5(8): 761 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. B. Levashova, N. Sharma, O. A. Timofeeva, J. S. Dome, and A. O. Perantoni ELR+-CXC Chemokines and Their Receptors in Early Metanephric Development J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2359 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Caselli, S. Fiorentini, C. Amici, D. Di Luca, A. Caruso, and M. G. Santoro Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF-{kappa}B pathway Blood, April 1, 2007; 109(7): 2718 - 2726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wehner, C. N. Morrell, T. Reynolds, E. R. Rodriguez, and W. M. Baldwin III Antibody and Complement in Transplant Vasculopathy Circ. Res., February 2, 2007; 100(2): 191 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dell'Eva, C. Ambrosini, S. Minghelli, D. M. Noonan, A. Albini, and N. Ferrari The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-{kappa}B pathway Carcinogenesis, February 1, 2007; 28(2): 404 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Scaife, J. N. Bulmer, S. C. Robson, B. A. Innes, and R. F. Searle Effector Activity of Decidual CD8+ T Lymphocytes in Early Human Pregnancy Biol Reprod, October 1, 2006; 75(4): 562 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. McCord, S. I. Resto-Ruiz, and B. E. Anderson Autocrine Role for Interleukin-8 in Bartonella henselae-Induced Angiogenesis Infect. Immun., September 1, 2006; 74(9): 5185 - 5190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Zeitlin, E. Joo, Z. Dong, K. Warner, G. Wang, Z. Nikolovska-Coleska, S. Wang, and J. E. Nor Antiangiogenic Effect of TW37, a Small-Molecule Inhibitor of Bcl-2. Cancer Res., September 1, 2006; 66(17): 8698 - 8706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yao, R.-H. Zhou, M. Petreaca, L. Zheng, J. Shyy, and M. Martins-Green Activation of sterol regulatory element-binding proteins (SREBPs) is critical in IL-8-induced angiogenesis J. Leukoc. Biol., September 1, 2006; 80(3): 608 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-Y. Bao, J. Yao, and Y.-F. Lee 1{alpha}, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis Carcinogenesis, September 1, 2006; 27(9): 1883 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Stamatovic, R. F. Keep, M. Mostarica-Stojkovic, and A. V. Andjelkovic CCL2 Regulates Angiogenesis via Activation of Ets-1 Transcription Factor J. Immunol., August 15, 2006; 177(4): 2651 - 2661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Lane, A. R. Anand, and R. K. Ganju Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis Int. Immunol., August 1, 2006; 18(8): 1315 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Eum, G. B. Rha, B. Hennig, and M. Toborek c-Src Is the Primary Signaling Mediator of Polychlorinated Biphenyl-Induced Interleukin-8 Expression in a Human Microvascular Endothelial Cell Line Toxicol. Sci., July 1, 2006; 92(1): 311 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. H. Masckauchan and J. Kitajewski Wnt/Frizzled Signaling in the Vasculature: New Angiogenic Factors in Sight Physiology, June 1, 2006; 21(3): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Brown, D. Fallin, I. Ruczinski, A. Hutchinson, B. Staats, F. Vitale, C. Lauria, D. Serraino, G. Rezza, G. Mbisa, et al. Associations of Classic Kaposi Sarcoma with Common Variants in Genes that Modulate Host Immunity. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 926 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Korherr, H. Gille, R. Schafer, K. Koenig-Hoffmann, J. Dixelius, K. A. Egland, I. Pastan, and U. Brinkmann Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. PNAS, March 14, 2006; 103(11): 4240 - 4245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Dobreva, G. Waeber, R. W. James, and C. Widmann Interleukin-8 Secretion by Fibroblasts Induced by Low Density Lipoproteins Is p38 MAPK-dependent and Leads to Cell Spreading and Wound Closure J. Biol. Chem., January 6, 2006; 281(1): 199 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Charalambous, L. B. Pen, Y. S. Su, J. Milan, T. C. Chen, and F. M. Hofman Interleukin-8 Differentially Regulates Migration of Tumor-Associated and Normal Human Brain Endothelial Cells Cancer Res., November 15, 2005; 65(22): 10347 - 10354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-P. Lee, D.-I. Tai, K.-H. Lan, A. F.-Y. Li, H.-C. Hsu, E.-J. Lin, Y.-P. Lin, M.-L. Sheu, C.-P. Li, F.-Y. Chang, et al. The -251T Allele of the Interleukin-8 Promoter Is Associated with Increased Risk of Gastric Carcinoma Featuring Diffuse-Type Histopathology in Chinese Population Clin. Cancer Res., September 15, 2005; 11(18): 6431 - 6441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Yoon, J. Hur, K.-W. Park, J.-H. Kim, C.-S. Lee, I.-Y. Oh, T.-Y. Kim, H.-J. Cho, H.-J. Kang, I.-H. Chae, et al. Synergistic Neovascularization by Mixed Transplantation of Early Endothelial Progenitor Cells and Late Outgrowth Endothelial Cells: The Role of Angiogenic Cytokines and Matrix Metalloproteinases Circulation, September 13, 2005; 112(11): 1618 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. He, T. E. Peterson, and Z. S. Katusic Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8 Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H968 - H972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shoshani, J. Pe'er, V. Doviner, J. Frucht-Pery, and A. Solomon Increased Expression of Inflammatory Cytokines and Matrix Metalloproteinases in Pseudophakic Corneal Edema Invest. Ophthalmol. Vis. Sci., June 1, 2005; 46(6): 1940 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Murphy, M. McGurk, J. Pettigrew, A. Santinelli, R. Mazzucchelli, P. G. Johnston, R. Montironi, and D. J.J. Waugh Nonapical and Cytoplasmic Expression of Interleukin-8, CXCR1, and CXCR2 Correlates with Cell Proliferation and Microvessel Density in Prostate Cancer Clin. Cancer Res., June 1, 2005; 11(11): 4117 - 4127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Moldobaeva and E. M. Wagner Difference in proangiogenic potential of systemic and pulmonary endothelium: role of CXCR2 Am J Physiol Lung Cell Mol Physiol, June 1, 2005; 288(6): L1117 - L1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Gallagher, Y. Bao, A. Prorock, P. Zigrino, R. Nischt, V. Politi, C. Mauch, B. Dragulev, and J. W. Fox Gene Expression Profiling Reveals Cross-talk between Melanoma and Fibroblasts: Implications for Host-Tumor Interactions in Metastasis Cancer Res., May 15, 2005; 65(10): 4134 - 4146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Brat, A. C. Bellail, and E. G. Van Meir The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis Neuro-oncol, April 1, 2005; 7(2): 122 - 133. [Abstract] [PDF]
|
|
|
|
|
|
R. Schruefer, N. Lutze, J. Schymeinsky, and B. Walzog Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8 Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1186 - H1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Galvez, L. Genis, S. Matias-Roman, S. A. Oblander, K. Tryggvason, S. S. Apte, and A. G. Arroyo Membrane Type 1-Matrix Metalloproteinase Is Regulated by Chemokines Monocyte-Chemoattractant Protein-1/CCL2 and Interleukin-8/CXCL8 in Endothelial Cells during Angiogenesis J. Biol. Chem., January 14, 2005; 280(2): 1292 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. M. Rao and U. R. Pendurthi Tissue Factor-Factor VIIa Signaling Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 47 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lefranc, T. Mijatovic, V. Mathieu, S. Rorive, C. Decaestecker, O. Debeir, J. Brotchi, P. Van Ham, I. Salmon, and R. Kiss Characterization of Gastrin-Induced Proangiogenic Effects In vivo in Orthotopic U373 Experimental Human Glioblastomas and In vitro in Human Umbilical Vein Endothelial Cells Clin. Cancer Res., December 15, 2004; 10(24): 8250 - 8265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y H Yang, H J Lai, C M Huang, L C Wang, Y T Lin, and B L Chiang Sera from children with active Henoch-Schonlein purpura can enhance the production of interleukin 8 by human umbilical venous endothelial cells Ann Rheum Dis, November 1, 2004; 63(11): 1511 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Deem and J. M. Cook-Mills Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species Blood, October 15, 2004; 104(8): 2385 - 2393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. Bobrovnikova-Marjon, P. L. Marjon, O. Barbash, D. L. Vander Jagt, and S. F. Abcouwer Expression of Angiogenic Factors Vascular Endothelial Growth Factor and Interleukin-8/CXCL8 Is Highly Responsive to Ambient Glutamine Availability: Role of Nuclear Factor-{kappa}B and Activating Protein-1 Cancer Res., July 15, 2004; 64(14): 4858 - 4869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Spruce, L. A. Campbell, N. McTavish, M. A. Cooper, M. V. L. Appleyard, M. O'Neill, J. Howie, J. Samson, S. Watt, K. Murray, et al. Small Molecule Antagonists of the {sigma}-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo Cancer Res., July 15, 2004; 64(14): 4875 - 4886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Motto ADAMTS-13, VWF, inflammation, and thrombosis Blood, July 1, 2004; 104(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
A. Bernardo, C. Ball, L. Nolasco, J. F. Moake, and J.-f. Dong Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow Blood, July 1, 2004; 104(1): 100 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Hjortoe, L. C. Petersen, T. Albrektsen, B. B. Sorensen, P. L. Norby, S. K. Mandal, U. R. Pendurthi, and L. V. M. Rao Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration Blood, April 15, 2004; 103(8): 3029 - 3037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakajima, T. Gotanda, H. Uchimiya, T. Furukawa, M. Haraguchi, R. Ikeda, T. Sumizawa, H. Yoshida, and S.-i. Akiyama Inhibition of Metastasis of Tumor Cells Overexpressing Thymidine Phosphorylase by 2-Deoxy-L-Ribose Cancer Res., March 1, 2004; 64(5): 1794 - 1801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Keane, J. A. Belperio, Y. Y. Xue, M. D. Burdick, and R. M. Strieter Depletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer J. Immunol., March 1, 2004; 172(5): 2853 - 2860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vitale, A. Schmid-Alliana, V. Breuil, M. Pomeranz, M.-A. Millet, B. Rossi, and H. Schmid-Antomarchi Soluble Fractalkine Prevents Monocyte Chemoattractant Protein-1-Induced Monocyte Migration via Inhibition of Stress-Activated Protein Kinase 2/p38 and Matrix Metalloproteinase Activities J. Immunol., January 1, 2004; 172(1): 585 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Strasly, G. Doronzo, P. Capello, D. Valdembri, M. Arese, S. Mitola, P. Moore, G. Alessandri, M. Giovarelli, and F. Bussolino CCL16 activates an angiogenic program in vascular endothelial cells Blood, January 1, 2004; 103(1): 40 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Doubrovina, M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma J. Immunol., December 15, 2003; 171(12): 6891 - 6899. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
